The economics of treating vasovagal syncope

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 3 II, 1997, Pages 849-850

  Sutton, Richard ^a   Petersen, Mark E V ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Pacemaker; Vasovagal syncope

Indexed keywords

ARTIFICIAL HEART PACEMAKER; CONFERENCE PAPER; COST; COST EFFECTIVENESS ANALYSIS; ECONOMICS; GENERATOR; HEART PACING; HOSPITALIZATION; HUMAN; INJURY; RECURRENT DISEASE; SYNCOPE;

CARDIAC PACING, ARTIFICIAL; COST-BENEFIT ANALYSIS; EQUIPMENT DESIGN; HEALTH CARE COSTS; HUMANS; PACEMAKER, ARTIFICIAL; PROSPECTIVE STUDIES; RECURRENCE; SYNCOPE, VASOVAGAL;

EID: 0030951072     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb03920.x     Document Type: Article

References (4)

1. Petersen MEV, Chamberlain-Webber R, Fitzpatrick AP, et al. Permanent pacing for cardio-inhibitory malignant vasovagal syndrome. Br Heart J 1994; 71: 274-281.
2. Benditt DG, Sutton R, Gammage M, et al. Cardiac pacing in vasovagal syncope: Multi-center assessment of a rate-drop response algorithm. (abstract) PACE 1996; 19:592.
3. Sutton R, Bourgeois I. Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block. An economic sensitivity analysis. Eur Heart J 1996; 17: 574-582.
4. Sutton R, Bourgeois I. Cost-effectiveness of AAI versus DDD pacing in sick sinus syndrome. (abstract) PACE 1995; 18:1192-8625.